Literature DB >> 25455883

Cost-effectiveness of PET and PET/computed tomography: a systematic review.

Oke Gerke1, Ronnie Hermansson2, Søren Hess3, Søren Schifter4, Werner Vach5, Poul Flemming Høilund-Carlsen4.   

Abstract

The development of clinical diagnostic procedures comprises early-phase and late-phase studies to elucidate diagnostic accuracy and patient outcome. Economic assessments of new diagnostic procedures compared with established work-ups indicate additional cost for 1 additional unit of effectiveness measure by means of incremental cost-effectiveness ratios when considering the replacement of the standard regimen by a new diagnostic procedure. This article discusses economic assessments of PET and PET/computed tomography reported until mid-July 2014. Forty-seven studies on cancer and noncancer indications were identified but, because of the widely varying scope of the analyses, a substantial amount of work remains to be done.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Computed tomography; Cost-benefit analysis; Cost-effectiveness; Economics; PET

Mesh：

Substances：

Year:  2014        PMID： 25455883     DOI： 10.1016/j.cpet.2014.09.008

Source DB:  PubMed          Journal:  PET Clin        ISSN： 1556-8598


  8 in total

1.  Added value of cost-utility analysis in simple diagnostic studies of accuracy: (18)F-fluoromethylcholine PET/CT in prostate cancer staging.

Authors:  Oke Gerke; Mads H Poulsen; Poul Flemming Høilund-Carlsen
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

2.  Carotid artery molecular calcification assessed by [18F]fluoride PET/CT: correlation with cardiovascular and thromboembolic risk factors.

Authors:  Simon A Castro; Daniele Muser; Hwan Lee; Emily C Hancin; Austin J Borja; Oswaldo Acosta; Thomas J Werner; Anders Thomassen; Caius Constantinescu; Poul Flemming Høilund-Carlsen; Abass Alavi
Journal:  Eur Radiol       Date:  2021-04-17       Impact factor: 5.315

3.  Global costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis.

Authors:  Zachary J Ward; Andrew M Scott; Hedvig Hricak; Rifat Atun
Journal:  Lancet Oncol       Date:  2021-03       Impact factor: 41.316

4.  Saving costs in cancer patient management through molecular imaging.

Authors:  Carl von Gall; Piotr Maniawski; Fred Verzijlbergen; Ignasi Carrio; Thomas Beyer; Antonis Kalemis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-14       Impact factor: 9.236

5.  Cancer metastasizes to the bone marrow and not to the bone: time for a paradigm shift!

Authors:  Poul Flemming Høilund-Carlsen; Søren Hess; Thomas J Werner; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06       Impact factor: 9.236

Review 6.  FDG-PET/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review.

Authors:  Fredrik Helland; Martine Hallin Henriksen; Oke Gerke; Marianne Vogsen; Poul Flemming Høilund-Carlsen; Malene Grubbe Hildebrandt
Journal:  Diagnostics (Basel)       Date:  2019-08-27

7.  Daniel's Lymph Node Biopsy: Why We Must Not Forget History.

Authors:  Christos Damaskos; Dimitrios Dimitroulis; Anna Garmpi; Vasiliki E Georgakopoulou; Alexandros Patsouras; Athanasios Syllaios; Nikolaos Garmpis
Journal:  Oman Med J       Date:  2022-01-31

8.  Addressing Global Inequities in Positron Emission Tomography-Computed Tomography (PET-CT) for Cancer Management: A Statistical Model to Guide Strategic Planning.

Authors:  Miguel Gallach; Miriam Mikhail Lette; May Abdel-Wahab; Francesco Giammarile; Olivier Pellet; Diana Paez
Journal:  Med Sci Monit       Date:  2020-08-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.